Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

计划入组 685 人 · 首次发布于 2017 年 10 月 31 日

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

计划入组 86 人 · 首次发布于 2025 年 9 月 10 日

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

计划入组 338 人 · 首次发布于 2022 年 1 月 25 日

Palbociclib(Ibrance)

C₂₄H₂₉N₇O₂ · Rx

HER2+ Breast Cancer(Diakonos)

CLX-001

Arvinas

United States

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

Puma Biotechnology Advances Cancer Pipeline with Two Phase II Trials for Alisertib

Puma Biotechnology Initiates Phase 2 Trial of Alisertib for HR+/HER2- Metastatic Breast Cancer

PADMA Trial: Palbociclib Plus Endocrine Therapy Significantly Extends Time to Treatment Failure in Advanced Breast Cancer